Background: There remains uncertainty around the appropriate choice of adjuvant therapies to offer postmenopausal women with node-positive early breast cancer. Objective and study design: To present the results derived from a discrete event simulation (DES) model that compared tamoxifen plus...

Background: MA17 was a randomised placebo-controlled trial of letrozole 2.5 mg/day in 5187 estrogen receptor-positive, 50% node-negative, postmenopausal women (median age 62 years at enrolment) with early breast cancer, post-5 years' adjuvant tamoxifen therapy. The objective of this evaluation...